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Abstract
Calcium-binding proteins are widely used to distinguish neuronal subsets in the brain. This study focuses on secretagogin, 
an EF-hand calcium sensor, to identify distinct neuronal populations in the brainstem of several vertebrate species. By using 
neural tube whole mounts of mouse embryos, we show that secretagogin is already expressed during the early ontogeny of 
brainstem noradrenaline cells. In adults, secretagogin-expressing neurons typically populate relay centres of special senses 
and vegetative regulatory centres of the medulla oblongata, pons and midbrain. Notably, secretagogin expression overlapped 
with the brainstem column of noradrenergic cell bodies, including the locus coeruleus (A6) and the A1, A5 and A7 fields. 
Secretagogin expression in avian, mouse, rat and human samples showed quasi-equivalent patterns, suggesting conservation 
throughout vertebrate phylogeny. We found reduced secretagogin expression in locus coeruleus from subjects with Alzhei-
mer’s disease, and this reduction paralleled the loss of tyrosine hydroxylase, the enzyme rate limiting noradrenaline synthesis. 
Residual secretagogin immunoreactivity was confined to small submembrane domains associated with initial aberrant tau 
phosphorylation. In conclusion, we provide evidence that secretagogin is a useful marker to distinguish neuronal subsets 
in the brainstem, conserved throughout several species, and its altered expression may reflect cellular dysfunction of locus 
coeruleus neurons in Alzheimer’s disease.
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Introduction
Our brainstem harbours a wealth of distinctly or ambigu-
ously demarcated cell groups with various functions serving 
basic physiological needs. Pathways of special senses have 
relay centres in the cranial brainstem: the superior colliculus 
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and the lateral geniculate nucleus of the visual system, and 
the inferior colliculus and the medial geniculate nucleus 
of the acoustic system are situated in the mesencephalon. 
Cranial nerve nuclei of different modalities are arranged 
in logical mediolateral and craniocaudal orders, reaching 
from the caudal medulla oblongata to the cranial midbrain. 
These include stations of specific sensory pathways, like the 
cochlear and vestibular nuclei in the caudal pons, or com-
plex vegetative centres, like the solitary tract nucleus in the 
medulla oblongata. Other autonomic integrative centres, like 
the periaqueductal grey involved in behavioural responses 
to threatening stimuli (Faull et al. 2019) and opioid modula-
tion of pain (Martins and Tavares 2017), or the parabrachial 
nuclear complex controlling fluid and food homoeostasis, 
cardiovascular functions (Davern 2014) and body tempera-
ture (Morrison and Nakamura 2011) appear as independent 
nuclei in the brainstem. Activating systems using biogenic 
amines as neurotransmitters have their origin in the brain-
stem: noradrenaline- (A1–A6 fields), adrenaline- (C1–C3 
fields) or serotonin-containing (B1–B8 fields) neurons from 
nuclei, and their projections richly innervate many forebrain 
regions, the cerebellum and the spinal cord. The nuclei and 
centres of these different systems (Fig. 1) are intertwined 
and may in the brainstem even overlap, which has made their 
identification and separation an ongoing challenge.
The classical neuroanatomical toolbox including, e.g., 
ubiquitous neuronal staining or metal-based impregnations, 
was the first pioneering step to identify major brainstem 
centres. The advent of tract tracing and immunohistochem-
istry opened a new dimension in understanding the layout of 
brainstem circuits. Researchers not only identified hitherto 
unknown nuclei, but were able to demarcate subregions, fur-
ther unravelling cellular heterogeneity within cell groups 
previously thought to be homogenous (Dahlstroem and Fuxe 
1964; Ljungdahl et al. 1978; Markia et al. 2008; Palkovits 
1999; Zaborszky et al. 1984). Although chemogenetic and 
optogenetic tools brought a quantum leap in the functional 
classification of neurons, neurochemical markers remain 
of foremost importance to identify neuronal populations in 
the brain (Rees et al. 2017), with calcium-binding proteins 
(CaBPs) being common-choice candidates to distinguish cell 
types or nuclei (Andressen et al. 1993; Freund and Buzsáki 
1996; Riedel et al. 2002).
Activation of signalling pathways is a typical calcium 
 (Ca2+)-dependent mechanism with  Ca2+-sensor proteins 
specifying downstream protein–protein interactions (Skelton 
et al. 1994). Secretagogin, a  Ca2+-sensor protein (Wagner 
et al. 2000), undergoes conformational changes upon  Ca2+ 
binding (Rogstam et al. 2007) to primarily affect protein 
turnover and exocytosis (Gartner et al. 2007). In agreement 
with its involvement in the exocytotic machinery, secre-
tagogin, found in the mammalian rodent and non-primate 
(Hanics et al. 2017; Mulder et al. 2009, 2010) and human 
(Attems et al. 2012a) brain and spinal cord (Zhang et al. 
2016), has been associated with presynaptic neurotrans-
mitter release (Romanov et al. 2015; Zhang et al. 2016). 
Nevertheless, while forebrain distribution of secretagogin-
expressing(+) neurons is well characterized (Alpar et al. 
2012; Attems et al. 2008; Garas et al. 2016; Gyengesi et al. 
2013; Kosaka and Kosaka 2013; Kosaka et al. 2017; Mulder 
et al. 2009; Romanov et al. 2015), the localization and phe-
notype of  secretagogin+ neurons in the brainstem remain 
elusive.
Here, we use secretagogin as a valuable neuroanatomical 
marker to identify brainstem nuclei in vertebrates, including 
avian, rodent and human brains. In addition to relay cen-
tres of special senses and vegetative regulatory centres, we 
classify the brainstem noradrenaline stress axis as a focus 
of secretagogin expression in the murine and human brain. 
Noradrenergic neurons, assembled in a column of nuclei 
throughout the medullary and pontine brainstem (Dahl-
stroem and Fuxe 1964), are extensively connected to corti-
cal and subcortical forebrain regions to orchestrate central 
responses to, e.g. stress (Aston-Jones et al. 1996; Itoi and 
Sugimoto 2010; Samuels and Szabadi 2008a, b). Imbalance 
in noradrenaline function may result in affective, panic and 
anxiety disorders (Bremner et al. 1996a, b; Charney 2003; 
Kvetnansky et al. 2009; Samuels and Szabadi 2008a, b), 
representing serious and costly morbidities and a burden 
on public health worldwide (Alloul et al. 1998; Takizawa 
et al. 2015). Of note, locus coeruleus is critically vulnerable 
already in the initial phase of neurodegenerative diseases, 
most notably Alzheimer’s disease (Braak and Del Tredici 
2012; Tomlinson et al. 1981). We suggest that altered secre-
tagogin expression in locus coeruleus neurons is a clinico-
pathological sign of Alzheimer’s disease paralleling or even 
preceding tyrosine hydroxylase (TH) loss.
Results
Secretagogin is expressed in the locus coeruleus 
of the early rhombencephalic neural tube
We have isolated and prepared neural tube whole mounts 
from early mouse embryos to determine the onset of secreta-
gogin expression in the foetal brainstem (Fig. 2). At embry-
onic day 8.5 (E8.5), no secretagogin immunoreactivity 
could be detected in any rhombencephalic domain (Fig. 2a). 
Brainstem neurons began to express secretagogin by E11.5, 
with a “hot spot” in the caudal midbrain (Fig. 2b) and in 
cell contingents along the basal plate and limiting sulcus of 
the medulla oblongata and the cervical flexure. At E11.5, 
TH expression was detected in a cell population dispersed 
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throughout the medulla oblongata and pons. Those  TH+ 
cells that had concentrated in the locus coeruleus (Fig. 2b, 
 b1) were secretagogin immunoreactive (Fig. 2b1’,  b1’’) with 
 TH+/secretagogin− cells being the exception rather than the 
rule. We conclude that secretagogin and TH are expressed 
coincidentally in the major noradrenergic brainstem centre 
during mouse ontogeny.
Fig. 1  Distribution of secre-
tagogin in the rat brainstem 
I.  Secretagogin+ somata were 
identified in coronal sections 
throughout the rat brainstem. 
Low-power micrographs are 
paired with schemata of coronal 
brain sections to indicate cranio-
caudal levels.  Secretagogin+ 
neurons-containing regions are 
indicated in purple. Superior 
colliculus, the microcel-
lular tegmental nucleus, the 
dorsal nucleus of vagus and 
the noradrenergic cell groups 
including A1, A5, A6 and A7 
typically expressed secretago-
gin. For high-power images, 
please see Fig. 4. A1, A5, A7 
noradrenergic cell groups, 
C1 adrenergic cell group, Cn 
cuneiform nucleus, DLPAG dor-
solateral periaqueductal grey, IC 
inferior colliculus, IP interpe-
duncular nucleus, iRT interme-
diate reticular nucleus, LC locus 
coeruleus, LL lateral lemniscus, 
LPMC lateral posterior thalamic 
nucleus mediocaudal part, 
MiTg microcellular tegmental 
nucleus, mRT mesencephalic 
reticular formation, MV medial 
vestibular nucleus, NTS solitary 
tract nucleus, PB parabrachial 
nucleus, PP peripeduncular 
nucleus, Ptg pedunculopontine 
tegmental nucleus, sB subbra-
chial nucleus, SC superior col-
liculus, sp5 spinal tract nucleus 
of V, VLPAG ventrolateral 
periaqueductal grey, X dorsal 
nucleus of X
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Distribution of  secretagogin+ neurons in the rodent 
brainstem
Our systematic survey through the rat brainstem revealed 
several medullary, pontine and midbrain domains which har-
boured  secretagogin+ neurons (Fig. 1). In sagittal sections, 
i.a. the superior colliculus, the parabrachial nucleus and the 
A5 field emerged as secretagogin ‘hot spots’ (Fig. 3). Using 
serial coronal sections of the brainstem (Fig. 1), we identi-
fied secretagogin immunoreactivity in the superior colliculus 
and in the dorsolateral part of the periaqueductal grey in the 
midbrain (Fig. 4a–a1’’), the locus coeruleus, parabrachial 
nucleus in the pons (Fig. 4b, c), and the dorsal nucleus of 
vagus in the medulla oblongata (Fig. 4d1,  d1’). We identified 
identical distributions of immunoreactive cells when using 
our primary antibodies produced either in rabbit or goat, 
although the goat antiserum was associated with higher tis-
sue background (Fig. 4a,  a1, b,  b1, d,  d1). In addition, several 
smaller groups of  secretagogin+ neurons appeared in the 
medulla oblongata and pons, which were identified as the 
A1 (Fig. 4e), A5 and A7 fields. Secretagogin/TH double 
immunolabelling in the locus coeruleus (Fig. 4f–f’’) showed 
that 75.5 ± 6.9% (average ± SEM) of all labelled cells co-
expressed these markers, leaving 23.3 ± 2.2% and 1.1 ± 0.9% 
of cells single labelled for TH and secretagogin, respectively. 
The processes of  secretagogin+ locus coeruleus neurons 
were typically directed towards the ventricular space, likely 
representing dendrites (Fig. 4f1). At the same time,  TH+ 
neurons in the ventral tegmentum of the midbrain did not 
co-express secretagogin (Fig. S1a–a’’). Likewise,  serotonin+ 
median raphe neurons were also immunonegative for secre-
tagogin (Fig. S1b–b’’). Furthermore, in the ventral part of 
the periaqueductal grey, where  serotonin+ and  secretagogin+ 
neurons coincidentally occurred, we could not identify their 
co-expression either (Fig. S1c–c’’).
Fig. 2  Secretagogin expression in the early neural tube. a Neural tube 
whole mount from E8.5 mouse embryos lacks secretagogin immuno-
reactivity. b Secretagogin expression appears at E11.5 in the caudal 
midbrain. b1–b1’’  TH+ neurons share secretagogin immunoreactivity 
in the locus coeruleus. caud caudal, rostr rostral, Scgn secretagogin, 
TH tyrosine hydroxylase. Scale bars 300 μm (a, b), 60 μm (b1)
Fig. 3  Distribution of secretagogin in the rat brainstem II. Sagittal sections of the rat brain revealed superior colliculus (a1), the parabrachial 
nucleus (a2) and the A5 field (a3) as typical loci which harbour  secretagogin+ neurons. Scale bars 1 mm (a), 300 µm (a1, a2, a3)
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Fig. 4  Distribution of secretagogin in the rat brainstem III. (a–a1’’) 
In the midbrain,  secretagogin+ neurons condensed in the superior col-
liculus and the dorsolateral periaqueductal grey. b–c Pontine distribu-
tion of secretagogin expression. Locus coeruleus, and lateral to it the 
parabrachial nucleus (c) contained many  secretagogin+ cells. (d–d1’) 
In the medulla oblongata, the dorsal nucleus of vagus was clearly 
outlined by its content of  secretagogin+ neurons. e  Secretagogin+ 
cells in the A1 field. f–f’’ Secretagogin was typically expressed 
in  TH+ neurons in the locus coeruleus (white arrowheads indicate 
 TH+/secretagogin+ neurons, black arrowheads point to  TH+/secreta-
gogin− neurons). f1 The processes of  secretagogin+ locus coeruleus 
neurons reached the ventricular surface (white arrowheads). LC locus 
coeruleus, scgn secretagogin, PAG periaqueductal grey. Scale bars 
1 mm (a1, b1, d1), 100 µm (a1’), 40 µm (a1, b1’), 30 µm (c, d1’, e, f’’), 
10 µm (a1’’), 3 µm (f1)
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Relation of secretagogin to other CaBPs
CaBPs are routinely used to typify neurons in the brain 
(Skelton et al. 1994). They exhibit largely non-overlap-
ping expression patterns (Andressen et al. 1993; Freund 
and Buzsáki 1996) with occasional co-localization in the 
olfactory circuit, ventral pallidum and renewing cells of 
the dentate gyrus (del Rio and DeFelipe 1997; Wouterlood 
et al. 2001). In the brainstem,  secretagogin+ neurons form 
largely non-overlapping populations with only occasional, 
domain-specific overlap/co-expression of CaBPs in select 
nuclei (Fig. 5): in the dorsal nucleus of vagus and com-
missural part of the solitary tract nucleus, a complemen-
tary expression pattern of calretinin and secretagogin was 
shown (Fig. 5a–a1’’), with many  calretinin+/secretagogin+ 
double-labelled neurons in the dorsolateral part of the soli-
tary tract nucleus at the same level (Fig. 5c–c1’’’). By using 
simultaneous labelling for secretagogin/calretinin/parvalbu-
min, 68.5 ± 5.4% of all  secretagogin+ neurons co-expressed 
calretinin. Secretagogin/parvalbumin co-expression was 
exceptionally rare: we only identified a single  secretagogin+ 
neuron which also harboured parvalbumin (Fig. 5c1’,  c1’’). 
We found a diverse co-expression pattern in the spinal tract 
nucleus of the trigeminus: using secretagogin/calretinin/
parvalbumin or secretagogin/calbindin D28k/parvalbu-
min immunohistochemistry, secretagogin often co-local-
ized with calbindin D28k (Fig. 5e–e2, 40.3 ± 15.9% of all 
 secretagogin+ neurons co-expressed calbindin D28k), only 
sporadically with calretinin (Fig. 5b–b2, 2.8 ± 3.2% of all 
 secretagogin+ neurons co-expressed calretinin), but not with 
parvalbumin (Fig. 5b–b1’’, e–e2). Similarly,  secretagogin+ 
neurons were immunonegative for parvalbumin in the ven-
trolateral medulla (Fig. 5d), as well as in the parabrachial 
nucleus (Fig. 5f).  Secretagogin+ neurons in the parabrachial 
nucleus did not share calretinin (Fig. 5f–f1’’) or calbindin 
immunoreactivity (Fig. 5g), either. We acknowledge that 
the above proportions were calculated using an investiga-
tive method and not by stereology; thus, it provides approx-
imate instead of accurate results regarding cell numbers/
proportions.
Secretagogin in the mouse and avian brainstem
We next asked if secretagogin expression exhibited quasi-
equivalent distribution in different vertebrates. To this end, 
serial sections of the mouse, chick and human brainstem 
were analysed for  secretagogin+ neurons to see if an evo-
lutionary continuum may exist among vertebrates. First, 
we generated a mouse line which expressed regulatory ele-
ments of the secretagogin promoter fused with EGFP on 
an artificial bacterial chromosome (ScgnBAC/egfp) to control 
for and validate our immunoreagents. We found exten-
sive overlap between EGFP expression and secretagogin 
immunoreactivity (Fig. 6a–a1’’, Fig. S2) in brainstem nuclei 
(Table S1). The lack of secretagogin immunoreactivity in 
 EGFP+ cells was attributed to low protein abundance in 
 EGFP+ neurons, i.e. below immunocytochemical detectabil-
ity (in our hands), because there was no hindbrain area in 
which the complete segregation of EGFP, suggesting ectopic 
expression, was seen. The distribution pattern of immuno-
reactive cells was largely similar to what we found in rats: 
 secretagogin+ neurons typically occurred in the microcel-
lular tegmental nucleus (Fig. 6a–a1’’, d,  d1), nucleus of the 
solitary tract (6b,  b1), the dorsal nucleus of vagus (Fig. 6c, 
 c1), the noradrenergic fields, especially locus coeruleus 
(Fig. 6e), and the superior colliculus (Fig. 6f,  f1). Yet, we 
detected differences between the two species: in the dorso-
lateral part of the periaqueductal grey, where immunoreac-
tive somata were found in rat but only immunoreactive fibres 
and terminals in the mouse brain (Fig. S3a, a’). In rats, the 
interpeduncular nucleus contained  secretagogin+ cell bodies 
in its dorsal versus  secretagogin+ cell bodies and fibres in its 
lateral division: no such immunoreactivity was detected in 
the corresponding region of mice (Fig. S3b, b’). Similarly, 
no immunoreactivity was detected in the inferior colliculus 
(Fig. S3c, c’) and medial vestibular nucleus (Fig. S3d, d’) 
of mice.
Secretagogin in the domestic chicken
CaBPs are molecules whose structures show significant evo-
lutionary conservation (Andressen et al. 1993). Neuronal 
subtypes of select brain areas typically retain their CaBP 
expression profiles across vertebrate species (Andressen 
et al. 1993; Gati et al. 2014). The brainstem harbours veg-
etative centres and nuclei, which share similarity, or even 
identity, in both lower and higher order vertebrates. We 
selected the domestic chick (Gallus domesticus) as a pre-
cocial avian species with immediate maturity after hatching 
to verify our hypothesis that secretagogin has an evolution-
ary preserved neuron-specific distribution in the vertebrate 
brainstem. Thus, the vagal nucleus (Fig. 7a,  a1), the ventro-
lateral medulla (Fig. 7b,  b1), the vestibular nuclei and the 
locus coeruleus (Fig. 7c), midbrain nuclei like the ventral 
tegmental area and periaqueductal grey (Fig. 7d–d2) were 
typical secretagogin-expressing foci. Of note, we found 
 secretagogin+ neurons in areas which cannot be directly cor-
related to mammalian brain structures. Thus, the supraspi-
nal nucleus—innervating the upper neck muscles, but being 
separate from the nucleus where the accessory nerve arises 
(Wild 1981)—also contained immunoreactive cells (not 
shown) and smaller islets of  secretagogin+ neurons were 
identified in different subdivisions of the reticular forma-
tion, especially in the midbrain (Fig. 7e). In conclusion, 
secretagogin is an evolutionarily conserved protein in many 
vertebrate brainstem nuclei.
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Fig. 5  Co-expression of secretagogin with classical  Ca2+-binding 
proteins in select brainstem nuclei of the rat. a–a1’’ Complementary 
distribution of calretinin and secretagogin in the commissural part 
of the solitary nucleus and the dorsal nucleus of vagus (white arrow-
heads indicate  secretagogin+/calretinin− neurons, black arrowhead 
points to a  secretagogin+/calretinin+ neuron). b–b1’  Secretagogin+ 
neurons typically remained calretinin immunonegative (white arrow-
heads) in the spinal tract nucleus of the trigeminus, with exceptional 
co-expression only (black arrowhead). b2 Single- and co-expression 
ratios of secretagogin and calretinin in the spinal tract nucleus of 
the trigeminus. 100% percentage refers to all labelled cells detected 
for secretagogin and/or calretinin immunoreactivity.  Secretagogin+/
calretinin+ neurons: 2.8 ± 3.2%,  secretagogin+/calretinin− neurons 
51.2 ± 6.1%,  secretagogin−/calretinin+ neurons 47.5 ± 5.4% (as of 
average ± s.e.m.). c–c1’’’  Calretinin+ neurons in the dorsolateral part 
of the solitary tract nucleus can either remain immunonegative for 
secretagogin (white arrowheads) or co-express it (black arrowheads) 
Grey arrowhead points to a  CR−/Scgn−/PV+ neuron. c2 Single- and 
co-expression ratios of secretagogin and calretinin in the dorsolat-
eral part of the solitary tract nucleus. 100% percentage refers to all 
labelled cells detected for secretagogin and/or calretinin immunoreac-
tivity.  Secretagogin+/calretinin+ neurons: 36.1 ± 2.3%,  secretagogin+/
calretinin− neurons 16.9 ± 3.5%,  secretagogin−/calretinin+ neurons 
43.7 ± 2.1% (as of average ± s.e.m.). d  Secretagogin+ neurons (white 
arrowheads) in the A1 field did not co-express parvalbumin (black 
arrowheads point to  secretagogin−/parvalbumin+ somata). e–e1’’ 
 Secretagogin+ neurons typically co-expressed calbindin in the spinal 
tract nucleus of the trigeminus (black arrowheads). White arrow-
heads point to  calbindin+/secretagogin− somata, grey arrowhead 
to a  secretagogin+/calbindin− soma. e2 Single- and co-expression 
ratios of secretagogin and calbindin in the spinal tract nucleus of 
the trigeminus. 100% percentage refers to all labelled cells detected 
for secretagogin and/or calbindin immunoreactivity.  Secretagogin+/
calbindin+ neurons: 19.1 ± 8.0%,  secretagogin+/calbindin− neurons 
30.7 ± 11.3%,  secretagogin−/calbindin+ neurons 50.2 ± 7.2% (as of 
average ± s.e.m.). f–f1’’  Secretagogin+ neurons showed a comple-
mentary distribution to  calretinin+ neurons in the lateral parabrachial 
nucleus (white arrowheads point to  secretagogin+/calretinin− somata, 
black arrowheads point to  secretagogin−/calretinin+ somata). g 
 Secretagogin+ neurons remain immunonegative for calbindin in the 
parabrachial nucleus. CB calbindin, CR calretinin, NTS solitary tract 
nucleus, NTSc commissural part of the solitary tract nucleus, Scgn 
secretagogin, PV parvalbumin, X dorsal nucleus of vagus, XII hypo-
glossal nucleus. Scale bars 150 µm (a, b, c, e), 70 µm (g), 40 µm (d, 
f), 10 µm (a1’’, b1’, c1, e1’’, f1’’)
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Secretagogin expression is reduced 
in noradrenergic brainstem nuclei in Alzheimer’s 
disease
Immersion fixation of blocked tissue, the routine process-
ing procedure, and post-mortem delay adversely impact 
epitope detection by immunohistochemistry in human 
brain tissue. We overcame this problem by applying vas-
cular perfusion via the internal carotid and vertebral arter-
ies to preserve tissue integrity. Similarly to laboratory 
rodents, we found  secretagogin+ neurons in the noradr-
energic axis of the human brainstem (Fig. 8a–c), includ-
ing the locus coeruleus (Fig. 8b,  b1), and A1 (Fig. 8a2) 
and A7 (Fig. 8c) nuclei.  TH+ locus coeruleus neurons 
co-expressed secretagogin, with subcellular foci (patches) 
restricted to peripheral intrasomatic domains and neu-
ronal processes, frequently apposing the cell membrane 
(Fig. 8d–d1’’). In addition, we identified  secretagogin+ 
neurons in the dorsal nucleus of vagus of the human brain 
(Fig. 8a,  a1), similarly to what we found in rat (Fig. 4d1’) 
and mouse (Fig. 6c1).
We hypothesized that neurodegenerative stimuli may 
be harmful for secretagogin expression in LC neurons. 
Alternatively, secretagogin could spare these cells from 
neurodegeneration.  Secretagogin+ hippocampal or olfac-
tory neurons are preserved in neurodegenerative dis-
orders, like Alzheimer’s disease (Attems et  al. 2008, 
2012a), supporting the latter hypothesis. However, it has 
Fig. 6  Secretagogin expression in the mouse brain stem. a–a1’’ 
EGFP-expressing neurons in secretagogin–EGFP mice showed secre-
tagogin immunoreactivity as exemplified in the microcellular teg-
mental nucleus (white arrowheads in a–a1’’). Occasionally, EGFP-
expressing neurons remained secretagogin immunonegative (black 
arrowhead in a–a1’’). b–f1  Secretagogin+ neurons in the solitary tract 
nucleus (b, b1), dorsal nucleus of vagus (c, c1), microcellular tegmen-
tal nucleus (d, d1), locus coeruleus (e) and the superior colliculus (f, 
f1). LC locus coeruleus, MiTg microcellular tegmental nucleus. Scale 
bars 1 mm (b–f), 100 µm (a’’, d1, f1), 70 µm (b1), 40 µm (c1)
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been proposed that  TH+ locus coeruleus neurons are most 
sensitive and compromised already in the early phase in 
Alzheimer’s disease (Tomlinson et al. 1981): tau pathol-
ogy appears earliest in locus coeruleus noradrenaline 
neurons (Attems et al. 2012b). Monitoring secretagogin 
expression at the transcription (RNA) level, we found that 
it robustly decreased already in Braak III–IV stage sub-
jects and further diminished in severe Alzheimer’s disease 
(Fig. 8h). In severe Alzheimer’s disease subjects (Braak 
V–VI), we identified a parallel decrease in TH (relative 
fluorescence intensity values: 103.59 ± 5.82 in Braak I–II 
vs. 52.66 ± 1.55 in Braak V–VI) and secretagogin (rela-
tive fluorescence intensity values: 47.13 ± 0.03 in Braak 
I–II vs. 27.42 ± 1.06 in Braak V–VI) immunoreactivity 
(Fig. 8e–g’’). In individuals with advanced stage of Alz-
heimer’s disease-related pathology (Braak V–VI), neurons 
with abundant cytoplasmic secretagogin immunoreactivity 
were very rare and often lacked AT8-immunoreactivity 
(hyperphosphorylated tau) (Fig. 8i, i’). Typically, secre-
tagogin expression within  TH+ neurons, if detectable, was 
restricted to very small intracellular compartments. These 
foci often overlapped with the  AT8+ microdomains where 
tau hyperphosphorylation started to develop within the 
neuron (Fig. 8f1–f1’’, but see also Fig. 8f2–f2’’). Secreta-
gogin expression was more evident in neuronal processes 
which occasionally showed multiple islets of  AT8+ pro-
files (Fig. 8j–j’’). In conclusion, secretagogin expression 
decreased with the progression of Alzheimer’s disease, 
with residual immunoreactivity in degenerating intracel-
lular microdomains.
Discussion
The present study underlines the usefulness of secretago-
gin as a novel neurochemical marker to distinguish subsets 
of neurons in the vertebrate brain. Detected already during 
early ontogeny, secretagogin in adults was then expressed 
in important relay centres in the lower brain stem, notably 
in several of the noradrenaline groups, with the A6 locus 
coeruleus being of particular interest. Moreover, secreta-
gogin expression in the locus coeruleus from Alzheimer’s 
disease subjects paralleled TH loss and was associated 
with initial, aberrant tau phosphorylation.
Fig. 7  Secretagogin expression in the chicken brain stem. a–e The 
distribution of  secretagogin+ neurons in the avian brain was similar 
to what we found in the mammalian brain. a–b1 In the medulla oblon-
gata, immunoreactive neurons populated the dorsal nucleus of vagus 
(black arrowhead in a, open arrowheads indicate nerve fibres emanat-
ing from the nucleus) and the ventrolateral medulla (b, b1). c In the 
pons, immunoreactivity was typically confined to the vestibular area 
and the locus coeruleus. d–e In the midbrain, neurons of the periaq-
ueductal grey matter, of the ventral tegmental area and scattered cells 
in the reticular formation showed secretagogin immunoreactivity. LC 
locus coeruleus, PAG periaqueductal grey, VTA ventral tegmental 
area. Scale bars 1 mm (a–e), 50 µm (a1, b1, d1, d2)
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Secretagogin is expressed early during ontogenesis 
and persists throughout adulthood in locus 
coeruleus neurons
CaBPs appear at different time points and last for different 
intervals during brainstem development. Calretinin, cal-
bindin and parvalbumin are sequentially expressed in the 
rat auditory brainstem during development, correlating with 
definite developmental stages (Lohmann and Friauf 1996). 
The postnatal development of rat vestibular nuclei and their 
cerebellar projections could be mapped by the specific spa-
tiotemporal appearance of the same CaBPs (Puyal et al. 
2002). Notably, the early onset of the expression of these 
CaBPs is no guarantee for their ongoing presence through 
adulthood. For example, even if most neurons, which 
express calbindin D28k during development preserve their 
phenotype (Enderlin et al. 1987), this is not the case in the 
superior olivary complex, where calbindin D28k expression 
is transient and may reflect critical periods in the control of 
calcium homoeostasis (Friauf 1993). Calretinin’s transient 
expression during ontogenesis is even more pronounced, in 
mammals (Lohmann and Friauf 1996), fish (Porteros et al. 
1998) and avian species (Bastianelli and Pochet 1993). Par-
valbumin, in turn, may appear late (in fact postnatal) dur-
ing forebrain development (Lohmann and Friauf 1996) and 
is induced by specific afferent stimuli (Barker and Dreher 
1998; Manns and Gunturkun 2003; McHaffie et al. 2001). 
We here show that secretagogin appears early in mouse 
brainstem development and shows ongoing expression in 
mouse brainstem noradrenergic cells, notably of the locus 
coeruleus neurons. Speculatively, secretagogin may regulate 
calcium-dependent mechanisms or TH synthesis in noradr-
energic neurons, which are critical not only in adulthood but 
already in embryonic life.
Secretagogin expression in relay, vegetative 
and stress centres of the vertebrate brainstem
Secretagogin was expressed in nuclei with different func-
tions. We highlight that  secretagogin+ neurons (i) populate 
the brainstem nuclei which serve as major vegetative com-
mand centres, such as the parabrachial or the solitary tract 
nucleus, (ii) occur in critical relay stations in the pathway of 
special senses (vestibular and visual), (iii) outline the brain-
stem noradrenaline axis and (iv) that this expression pattern 
has been preserved in phylogenesis, from avian species to 
humans. At the same time, secretagogin was expressed nei-
ther in  serotonin+ raphe neurons nor in  TH+ neurons in the 
ventral tegmentum, i.e. dopamine neurons, and we could 
reconfirm (data not shown) that cholinergic neurons at the 
midbrain–hindbrain border, including the pedunculopontine 
nucleus (Ch5), the laterodorsal tegmental nucleus (Ch6) and 
the parabigeminal nucleus (Ch8), remained immunonegative 
for secretagogin (Kosaka and Kosaka 2018).
CaBPs are widely used as neurochemical markers to 
distinguish neuronal pools (Andressen et al. 1993; Celio 
1990; Jacobowitz and Winsky 1991), with their exact intra-
cellular function, however, remaining contradictory (Fre-
und et al. 1990) or largely unrevealed. In general terms, 
 Ca2+-sensor proteins, including secretagogin (Wagner et al. 
2000), undergo a conformational change upon cell activa-
tion (Rogstam et al. 2007) to trigger intracellular signalling 
events (Gartner et al. 2007; Hanics et al. 2017; Malenczyk 
et al. 2017). Thus, secretagogin can be critical to regulate 
vegetative functions and sensory processing at the brainstem 
level based on their specific expression in the above nuclei. 
To unravel secretagogin’s physiological role in brainstem 
nuclei, future experiments could investigate the vegetative, 
vestibular and visual systems. We would definitely consider 
loss-of-function and activity-dependence experiments which 
impact the vegetative control at the major supraspinal level 
(solitary tract nucleus), control of balance and relevant 
motor skills as well as visual functions controlled at the mid-
brain level (e.g. smooth pursuit). Finally, whilst we recently 
explored secretagogin’s role in a mechanism converting 
Fig. 8  Secretagogin expression in the human brainstem is compro-
mised in Alzheimer’s disease. a–a2  Secretagogin+ neurons of the 
medulla oblongate populated the dorsal nucleus of vagus (a1), cap-
tured from the immediate consecutive section after the section shown 
in a and the A1 field (a2). b, b1 In the pons,  secretagogin+ neurons 
typically occurred in the locus coeruleus. c  Secretagogin+ neurons 
in the A7 field. d–d1’’  TH+ neurons of the human locus coeruleus 
expressed secretagogin. Secretagogin immunoreactivity concentrated 
along the cell membrane and most typically where dendrites ema-
nated from the soma (arrowheads in d–d1’’). e–e’’ Secretagogin was 
abundantly expressed in  TH+ locus coeruleus neurons in individuals 
without histopathological signs of Alzheimer’s disease (Braak I–II) 
(arrowheads in e–e’’ point to secretagogin-immunoreactive loci in 
 TH+ soma. f1–f2’’ In subjects with severe Alzheimer’s disease (Braak 
V–VI),  secretagogin+ subcellular domains in  TH+ somata were sig-
nificantly reduced and often overlapped with the accumulation foci of 
 AT8+ hyperphosphorylated tau (arrowheads in f1–f2’’, black arrow-
head in f1–f1’’ points to a  secretagogin+/AT8− domain). g, g’ TH 
and secretagogin immunofluorescence showed a paralleled reduction 
in individual locus coeruleus neurons in Braak V–VI vs. Braak I–II 
subjects. g’’ In average, TH-immunoreactivity decreased in locus 
coeruleus somata in severe Alzheimer’s disease which was paralleled 
with a loss in secretagogin immunoreactivity. h Secretagogin mRNA 
expression decreased significantly with the progress of Alzheimer’s 
disease in locus coeruleus micropunches. i–i Complementary distri-
bution of AT8 and secretagogin immunoreactivity of locus coeruleus 
neurons in severe Alzheimer’s disease. j–j’’ Initial, discontinuous 
accumulation of  AT8+ tau protein (arrowheads) in  secretagogin+ neu-
ronal process in the locus coeruleus of a late-stage Alzheimer’s dis-
ease subject. e1, f1, h p < 0.05, Student’s t test. Scgn secretagogin, TH 
tyrosine hydroxylase. Scale bars 500 µm (a, b), 100 µm (a1, b1, c), 
25 µm (a2), 15 µm (d), 5 µm (d1’’, e–e’’, i–i’, f1–f2’’), 500 µm (a, b), 
3 µm (j’’). Images a, b, c and d–d1’’ were reproduced with permis-
sion from EMBO: Alpár et  al., Hypothalamic CNTF volume trans-
mission shapes cortical noradrenergic excitability upon acute stress. 
EMBO J. 2018 Nov 2;37(21). pii: e100087
◂
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hypothalamic activation into long-lasting cortical excitabil-
ity following acute stress (Alpar et al. 2018), secretagogin’s 
function in shaping the ascending and descending reticulo-
activating system is a promising field for future works.
Is secretagogin involved in somato‑dendritic release 
of neuropeptides?
It has been shown that secretagogin interacts with proteins 
implicated in i.a. docking of release vesicles (Bauer et al. 
2011; Romanov et al. 2015). In fact, there is evidence that 
secretagogin is localized in corticotropin-releasing hor-
mone (CRH) axon terminals at the median eminence and 
modulates release of this neuropeptide at this site (Romanov 
et al. 2015). The present results show that secretagogin in 
human locus coeruleus neuron cell bodies and dendrites has 
a patchy distribution not rarely close to the cell membrane. 
We have proposed that the neuropeptide galanin is released 
from soma and dendrites of rat (Vila-Porcile et al. 2009) and 
human (Barde et al. 2016) locus coeruleus neurons under 
stressful conditions. This type of release has been shown 
for oxytocin and vasopressin to occur in the hypothalamic 
magnocellular neurons (Ludwig and Leng 2006). It may be 
relevant to analyse if secretagogin in the locus coeruleus 
neurons is involved in the regulation of galanin release, since 
this peptide system is involved in mood disorders (Hokfelt 
et al. 2018; Holmes and Picciotto 2006; Kuteeva et al. 2010; 
Lu et al. 2007).
Secretagogin expression decreases in Alzheimer’s 
disease
Ca2+-sensor proteins work in an activity-dependent manner 
to control downstream signalling. Cell activity and excit-
ability are reduced in neurodegenerative diseases, including 
Alzheimer’s disease (de Haan et al. 2017). We found that 
secretagogin expression significantly decreased with disease 
progression, paralleling TH loss typical already in the early 
phase of Alzheimer’s disease (Braak and Del Tredici 2012; 
Chan-Palay and Asan 1989; German et al. 1992; Kelly et al. 
2017), which may reflect impaired cell function and activity.
Previous studies suggested that secretagogin is neuro-
protective in hippocampal pyramidal cells in Alzheimer’s 
disease (Attems et al. 2008) and secretagogin expression 
has recently been shown to parallel disease progression: 
P301L tau transgenic mice showed reduced secretagogin 
expression in hippocampal neurons (Attems et al. 2011). 
Whilst we found that structural malformations can be 
independent of secretagogin loss (neurons with robustly 
reduced or not detectable secretagogin expression did not 
necessarily contain  AT8+ hyperphosphorylated tau), small 
intracellular domains with residual secretagogin expres-
sion were identified as foci with initial tau aberrancies and 
islet-like multiple accumulation of  AT8+ tau repeatedly 
occurred in the  secretagogin+ processes. This may impli-
cate that secretagogin-expressing domains can resist struc-
tural degradation which refers to its previously suggested 
role in neuroprotection (Attems et al. 2008). Accumulating 
evidence suggest that a deregulation of calcium signalling 
may play a major role in Alzheimer’s disease progression; 
CaBPS such as parvalbumin, calbindin and calretinin are 
upregulated in the hippocampus of 3-month-old APPswe/
PS1dE9 transgenic mice, possibly to control cellular homoe-
ostasis and synaptic plasticity, but losing cellular capacity 
to pathophysiological processes by the age of 12 months 
(Verdaguer et al. 2015). Activity-dependent translocation 
of synaptonuclear factors from synapses to the nucleus is 
regulated by calmodulin-dependent mechanisms; altered 
synapse-to-nucleus signalling may lead to neurodegenera-
tive and neuropsychiatric diseases (Parra-Damas and Saura 
2019).  Ca2+/calmodulin-dependent protein kinase kinase 2 
controls important neuronal processes and its loss leads to 
aberrant transferrin phosphorylation and trafficking which 
makes it a potential biomarker for Alzheimer’s disease (Sab-
bir 2018). CaBPs-mediated mechanisms are also important 
in glial cells to resist neurological disorders. Calcium dys-
regulation triggers astrocyte activation which leads to neu-
roinflammation, release of synaptotoxic factors and loss of 
glutamate regulation which can finally culminate in neuro-
degeneration (Sompol and Norris 2018). Dysregulation of 
calcineurin signalling pathways in activated astrocytes and 
its interaction with the nuclear factor of activated T cells 
(NFATs) couple vascular pathology to neurodegeneration 
and cognitive loss (Kraner and Norris 2018). Calcium sensor 
proteins have been previously implicated in neuroprotection: 
dopamine neurons in the substantia nigra use calretinin to 
confer oestrogen’s effect to prevent cell loss (Yi et al. 2016) 
and calretinin cooperates with the NCX1 exchanger to resist 
neurodegeneration (Boscia et al. 2016).
We suggest that secretagogin’s involvement in Alzhei-
mer’s disease is (i) due to its calcium sensor rather than to 
its calcium buffer property. Secretagogin has been shown to 
regulate diverse cellular mechanisms and functions, includ-
ing migration or hormonal release, in distinct brain neuronal 
populations (Alpar et al. 2018; Hanics et al. 2017; Romanov 
et al. 2015). All these functions seemed to be linked to secre-
tagogin’s calcium sensor property. Second (ii), secretago-
gin’s involvement in Alzheimer’s disease is likely exerted 
by affecting noradrenergic cell function, hence modulating 
noradrenergic cortical input. In conclusion, secretagogin as 
a calcium sensor may act neuroprotectively by regulating 
downstream machineries in noradrenergic cells.
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Materials and methods
Animals, surgery and ethical approval 
of experimental studies
Eleven 6-week-old male rats (Wistar), three 12-week-old 
male wild-type mice (C57BL/6), a total of six embryos 
from three pregnant C57BL/6 mice, three 12-week-old male 
EGFP–secretagogin transgenic mice and three 14-day-old 
chicks (Gallus domesticus) were used. Food and water were 
available ad libitum and animals were kept under stand-
ard housing condition and using a 12/12 light/dark cycle. 
Experimental procedures, including stereotaxic injections 
and transcardial perfusion, were approved by the Ethical 
Review Board of the Semmelweis University and conformed 
to the European Convention for the Protection of Vertebrate 
Animals used for experimental and other scientific purposes 
(Protocols: ETS No. 170, ETS No.123, Tierversuchgesetz 
2012, BGBI, Nr. 114/2012). Animals during surgeries and 
transcardial perfusions were anesthetized intramuscularly 
(i.m.) or intraperitoneally (i.p.) with a mixture of ketamine 
(50 mg/kg b wt) and xylazine (4 mg/kg b wt). After surgery, 
brains were perfusion fixed transcardially with 4% paraform-
aldehyde (PFA) in 0.1 M phosphate buffer (0.1 M PB).
Production of the SB‑BAC‑SCGN‑EGFP transgenic 
mouse line
To generate transgenic mice expressing the EGFP (enhanced 
green fluorescent protein) under the control of the SCGN 
promoter, we used a BAC (Bacterial Artificial Chromosome) 
engineering technology (Lee et al. 2001). The B6Ng01-
268C03 (RIKEN BioResource Research Center) BAC 
clone was chosen, which contained the whole SCGN gene 
and downstream of it another harbouring gene (Hist1h2ba) 
which was removed later. In the BAC modification casette, 
the EGFP cDNA was inserted between the recombination 
arms and its ATG site was fused into the SCGN’s gene ATG 
site. Following the EGFP cDNA, a WPRE (woodchuck 
hepatitis virus (WHP) posttranscriptional regulatory ele-
ment), an hGH-PA (human growth hormone polyadenyla-
tion signal) and a neomycin selection marker flanked by 
flippase recognition sites were inserted into the construct. 
Recombination was carried out as described by Lee et al. 
(2001). After the insertion of the EGFP and other compo-
nents into the BAC, the neomycin marker was removed in 
the host cells by a flippase enzyme. This was followed by 
a second recombineering-based BAC modification step in 
which ~ 40 kb downstream region from the SCGN gene 
was removed, which contained the neighbour gene. In the 
same step, we inserted both ITR (inverted terminal repeat) 
sequences recognized by the Sleeping Beauty transposase 
to combine the BAC transgenesis with a transposon-based 
system for increased integration efficiency (Rostovskaya 
et al. 2012). Transgenic mice were derived by pronuclear 
microinjection of the SB-BAC-SCGN-EGFP BAC (circular, 
1 ng/μl), Sleeping Beauty transposase mRNA (5 ng/μl) into 
C57BL/6Ntac fertilized eggs.
Immunohistochemistry and imaging
Chromogenic or multiple immunofluorescence histochemis-
try with select combinations of primary antibodies (Table 1) 
was performed according to published protocols (Alpar et al. 
2010; Lendvai et al. 2013). Free-floating sections (30 μm) 
were rinsed in phosphate buffer (PB, pH 7.4) and pre-treated 
with 0.3% Triton X-100 (in PB) for 1 h at 22–24 °C to 
enhance the penetration of antibodies. Non-specific immu-
noreactivity was suppressed by incubating our specimens in 
a cocktail of 5% normal donkey serum (NDS; Jackson), 2% 
bovine serum albumin (BSA; Sigma) and 0.3% Triton X-100 
(Sigma) in PB for 1 h at 22–24 °C. Sections were exposed 
(16–72 h at 4 °C) to select combinations of primary antibod-
ies (Table 1, (Alpar et al. 2004; Hanics et al. 2017; Lend-
vai et al. 2013; Mulder et al. 2010; Romanov et al. 2015)) 
diluted in PB to which 0.1% NDS and 0.3% Triton X-100 
had been added. After extensive rinsing in PB, the sections 




Marker Source Host IH dilution References
Calbindin Synaptic systems guinea pig,  pc2 1:1000 Hanics et al. (2017)
Calretinin Synaptic systems guinea pig,  pc2 1:1000 Hanics et al. (2017)
Parvalbumin Millipore Mouse,  mc1 (AT8) 1:1000 Lendvai et al. (2013)
PHF tau Pierce Mouse,  mc1 (AT8) 1:1000 Lendvai et al. (2013)
Secretagogin L. Wagner Rabbit,  pc2 1:12,000 Romanov et al. (2015)
Secretagogin Cell signaling Rabbit,  pc2 1:1000 This study
Secretagogin R&D systems Goat,  pc2 1:100 Mulder et al. (2010)
Tyrosine hydroxylase MERCK/Millipore Rabbit,  pc2 1:1000 Alpar et al. (2004)
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were processed using chromogenic or immunofluorescence 
detection. In single-labelling experiments, the sections were 
exposed to biotinylated anti-rabbit IgG raised in donkey 
(1:1,000 [Jackson], 2 h at 22–24 °C) followed by pre-formed 
avidin–biotin complexes also incorporating horseradish per-
oxidase for 1 h at 22–24 °C. Immunosignals were visualized 
by 3,3′-diaminobenzidine (Sigma, 0.025%) as chromogen 
intensified with Ni-ammonium sulphate (0.05%, Merck) 
in the presence of 0.001%  H2O2 as substrate (dissolved in 
0.05 M Tris buffer, pH 8.0). In multiple immunofluorescence 
labelling experiments, immunoreactivities were revealed by 
carbocyanine (Cy) 2, 3 or 5-tagged secondary antibodies 
raised in donkey (1:200 [Jackson], 2 h at 22–24 °C). Glass-
mounted sections were coverslipped with glycerol/gelatin 
(GG-1; Sigma).
The results of chromogenic stainings were captured on an 
Olympus BX-51 microscope at 10×, 20× and 40× primary 
magnification. Sections processed for multiple immunofluo-
rescence histochemistry were inspected and images acquired 
on a 780LSM confocal laser-scanning microscope (Zeiss) with 
optical zoom ranging from 1× to 3× at 63× primary magnifica-
tion (Plan-Apochromat 63×/1.40), and pinhole settings limiting 
signal detection to 0.5–0.7 μm “optical thickness”. Emission 
spectra for each dye were limited as follows: Cy2 (505–530 nm), 
Cy3 (560–610 nm), and Cy5 (650–720 nm). Multi-panel figures 
were assembled in CorelDraw X5 (Corel Corp.).
We used the histogram toolbox of the ZEN software 
(ZEISS) to measure immunofluorescence in the locus coer-
uleus neurons of Braak I–II (n = 3) and Braak V–VI (n = 3) 
subjects. Images from all sections (n = 3 per subject) were 
captured using identical settings. Somata (n = 11 per section) 
were demarcated and their immunofluorescence, reflecting 
their TH and secretagogin immunoreactivity, were automati-
cally measured and their quotient calculated.
To measure the overlap of secretagogin–EGFP expression 
and secretagogin immunoreactivity, we developed secretago-
gin immunoreactivity using the anti-secretagogin antibody 
raised in rabbits on sections made from secretagogin–EGFP 
mice brainstem. Analyses were carried out on images captured 
at 20× primary magnification. EGFP-expressing and immuno-
reactive somata were labelled with different markers in differ-
ent layers (channels) using Photoshop which allowed co-local-
ization of the two markers. In all three animals and for every 
nucleus, EGFP expression/immunoreactivity of somata were 
identified and marked in a minimum of three corresponding 
sections which were consecutive serial 30 μm-thick-sections 
of a four series-section pool. Labelled cells were counted in 
the whole nucleus on the section. The occurrence of secreta-
gogin–EGFP expression or secretagogin immunoreactivity in 
double-labelled somata was calculated and expressed as aver-
age ± SEM. Co-localization coefficients between secretagogin, 
parvalbumin, calbindin and calretinin were measured and cal-
culated along the same principle, including animal number and 
the quantitative attributes of image analysis. We emphasize 
that this approach was an investigative method and did not aim 
to provide accurate results regarding cell numbers/proportions.
Human tissue preparation 
and immunohistochemistry
We applied direct perfusion via the internal carotid and 
vertebral arteries, which facilitated the preservation of 
tissue integrity relative to alternative fixation methods. 
Human brains (n = 2, gender and age: female/83 years and 
male/79 years, with a clinical history lacking neurodegenera-
tive disease, ethical approval: TUKEB 84/2014, Hungary) 
were first perfused with physiological saline, followed by 
a fixative containing 2% PFA and 0.1% glutaraldehyde in 
0.1 M Tris-buffered saline (TBS, pH 7.4) 7 h or 11 h after 
death. The removal and subsequent preparation of human 
tissues were in accordance with the relevant ethical guide-
lines of Semmelweis University (1998, Budapest, Hungary). 
Blocks from the medulla oblongata and pons were dissected 
out and post-fixed in 2% PFA in TBS for 72, followed by 
immersion in cryoprotective 30% sucrose in 0.1 M PB (pH 
7.4) overnight. Coronal sections (50 μm) were cut on a cry-
ostat microtome and processed for immunohistochemistry. 
Free-floating sections were rinsed in PB (pH 7.4) and pre-
treated with 0.3% Triton X-100 (in PB) for 1 h at 22–24 °C 
to enhance the penetration of antibodies. Non-specific 
immunoreactivity was suppressed by incubating our speci-
mens in a cocktail of 5% NDS (Jackson), 10% BSA (Sigma) 
and 0.3% Triton X-100 (Sigma) in PB for 1 h at 22–24 °C. 
Sections were exposed for up to 72 h (at 4 °C) to the cocktail 
of primary antibodies (Table 1) diluted in PB to which 0.1% 
NDS and 0.3% Triton X-100 had been added. After exten-
sive rinsing in PB, the immunoreactivities were revealed by 
chromogenic staining (as above) or by Cy2, 3 or 5-tagged 
secondary antibodies raised in donkey (1:200 [Jackson], 2 h 
at 22–24 °C). Lipofuscin autofluorescence was quenched 
by applying Sudan Black-B [1%, dissolved in 70% ethanol 
(Schnell et al. 1999)]. Glass-mounted sections were cov-
erslipped with Aquamount embedding medium (Dako). 
Sections were inspected and images acquired on a 710LSM 
confocal laser-scanning microscope (Zeiss) at 10× or 40× 
primary magnification and pinhole settings limiting signal 
detection to 0.5–0.7 μm. Emission spectra for each dye were 
limited as follows: Cy2/505–530 nm, Cy3/560–610 nm, and 
Cy5/650–720 nm. Multi-panel figures were assembled in 
CorelDraw X7 (Corel Corp.).
Samples from patients with Alzheimer’s disease and age-
matched controls (without clinical signs of neuropsychiatric 
disease) were acquired at the Brain Bank of the Institute 
of Neurology, Medical University of Vienna, Austria, and 
from the Human Brain Bank of Semmelweis University, 
Budapest, Hungary (a total of 34 samples were used, for 
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details see Table 2). For immunohistochemistry, pontine 
blocks including the locus coeruleus were immersion fixed 
in 4% PFA in PB for 2–3 weeks at room temperature. These 
cases had previously been characterized for Alzheimer’s 
disease-related pathologies (amyloid β (Aβ) plaque burden, 
intracellular tau accumulation) and other neurodegenerative 
conditions had been excluded. Tissues were obtained and 
used compliant with the Declaration of Helsinki and fol-
lowing institutional guidelines. The study was performed in 
the course of an approved study by the Ethical Committee 
of the Medical University of Vienna (No.1454/2018). All 
patient material was coded to ensure anonymity throughout 
tissue processing. For real-time quantitative PCR experi-
ments, locus coeruleus micropunches from human samples 
were homogenized in isolating buffer (Qiagen). RNA was 
extracted using the RNeasy mini kit (Qiagen) with a DNase 
I step performed to eliminate traces of genomic DNA30 and 
reverse transcribed using a high-capacity cDNA reverse 
transcription kit (Applied Biosystems). Reactions were 
performed after an initial denaturation at 95 °C for 10 min, 
followed by 40 cycles of 95 °C for 15 s denaturation, anneal-
ing and extension at calculated temperatures (60 s) and a 
dissociation stage (from 60 to 95 °C with 0.5 °C steps for 
10 s each; CFX96, Bio-Rad), with primer pairs amplify-
ing short fragments for the secretagogin gene (forward: 
5′-CTG TTA GAT GGC TCT GCC TGTC-3′, reverse: 5′-GTT 
ACA GGA TTG CCA TGA ATGC-3′). Samples without tem-
plate or reverse transcriptase served as negative controls. 
Expression levels were normalized to the housekeeping 
gene encoding glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, forward: 5′–AAC TTT GGC ATT GTG GAA GG–3′, 
reverse: 5′ACA CAT TGG GGG TAG GAA CA3′) obtained for 
every sample in parallel assays. Quantitative (q)PCR was 
performed on a Bio-Rad CFX 96 thermal cycler. Samples 
were run in triplicate to avoid processing-related deviations.
Whole mounts
Neural tissue explants were isolated from E8.5 and E11.5 
mouse embryos from pregnant mice (n = 4 in total) with a 
modified technique described elsewhere (Echevarria et al. 
2001). Briefly, neural tubes were opened by cutting the roof 
plate on ice-cold PBS. Once flattened as an open book, they 
were placed on Millicell cell culture plate inserts (Millipore, 
pore size 0.4 μm) and cultured for 3 days as on Neurobasal 
medium penicillin (100 U/mL), and streptomycin (100 μg/
mL) (all from Invitrogen) in an incubator at 37 °C, with 
5%  CO2 and 95% humidity. The neural tube explants were 
Table 2  Demography and use of human subjects
Case ID Stage Age (year) Gender Analysis
#130-03 Braak I–II 78 Male IHC
#84-03 Braak I–II 77 Male IHC
#129-03 Braak I–II 77 Female IHC
#15-05 Braak I–II 78 Female IHC
#126-05 Braak I–II 80 Female IHC
#14-05 Braak III–IV 78 Male IHC
#156-03 Braak III–IV 77 Male IHC
#131-05 Braak III–IV 79 Female IHC
#58-06 Braak III–IV 80 Female IHC
#100-07 Braak III–IV 81 Male IHC
#9-10 Braak V–VI 84 Male IHC
#124-07 Braak V–VI 81 Female IHC
#88-05 Braak V–VI 78 Male IHC
#103-06 Braak V–VI 81 Female IHC
#107-10 Braak V–VI 85 Female IHC
#1 Braak I 63 Male qPCR
#90 Braak I 78 Female qPCR
#98 Braak I 74 Male qPCR
#164 Braak I 85 Male qPCR
#165 Braak I 88 Female qPCR
#187 Braak I 62 Male qPCR
#189 Braak I 79 Female qPCR
#220 Braak I–II 63 Male qPCR
#90 Braak I 78 Female qPCR
#98 Braak I 74 Male qPCR
#164 Braak I 85 Male qPCR
#165 Braak I 88 Female qPCR
#187 Braak I 62 Male qPCR
#189 Braak I 79 Female qPCR
#220 Braak I–II 63 Male qPCR
#94 Braak III–IV 65 Male qPCR
#185 Braak III–IV 80 Male qPCR
#196 Braak III–IV 78 Female qPCR
#197 Braak III–IV 64 Male qPCR
#222 Braak III–IV 80 Male qPCR
#163 Braak V–VI 81 Female qPCR
#177 Braak V–VI 89 Female qPCR
#188 Braak V–VI 86 Female qPCR
#192 Braak V–VI 81 Male qPCR
#195 Braak V–VI 83 Male qPCR
#201 Braak V–VI 74 Male qPCR
#185 Braak III–IV 80 Male qPCR
#196 Braak III–IV 78 Female qPCR
#197 Braak III–IV 64 Male qPCR
#222 Braak III–IV 80 Male qPCR
#163 Braak V–VI 81 Female qPCR
#177 Braak V–VI 89 Female qPCR
#188 Braak V–VI 86 Female qPCR
#192 Braak V–VI 81 Male qPCR
#195 Braak V–VI 83 Male qPCR
Table 2  (continued)
Case ID Stage Age (year) Gender Analysis
#201 Braak V–VI 74 Male qPCR
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subsequently removed from the membranes, fixed in PFA4% 
and immunostained as described above.
Statistical analysis
Data were analysed using Statistical Package for the Social 
Sciences (version 17.0, SPSS Inc.). Immunofluorescence 
intensities were evaluated using Student’s t test (on inde-
pendent samples, *p < 0.05). qPCR data were analysed using 
one-way ANOVA with Tukey’s post hoc tests. Data were 
expressed as mean ± SEM. A p value of < 0.05 was consid-
ered statistically significant.
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